BD (Becton, Dickinson and Company)
HQ US40% share
Major medical device company with captive EO sterilization; Sandy Utah facility; at risk of shutdown from EPA regulations (FDA warned against closure); IV catheters and other critical devices
manufactured · input
Pen Needles (Subcutaneous Injection)
Fine-gauge disposable pen needles used with GLP-1 injection pens.
6
Source countries
6
Companies
1
Goods affected
0
Claims on record
What depends on it
Goods that need this input
1 essential American goods rely on pen needles (subcutaneous injection) somewhere upstream in their supply chain.
Where it comes from
Source countries
Share of global supply, by country.
| Country | Share of supply |
|---|---|
| IEIreland | 40% |
| DKDenmark, except Greenland | 12% |
| JPJapan | 10% |
| GBUnited Kingdom | 8% |
| PLPoland | 8% |
| CHSwitzerland | 7% |
Who makes it
Supplier companies
6 companies produce pen needles (subcutaneous injection).
Novo Nordisk(NVO)
HQ DK12% share
World's largest insulin manufacturer. Controls ~33.7% of global diabetes care market; ~45% of human insulin. Operates the world's largest insulin production facility in Kalundborg, Denmark (produces ~50% of global insulin supply). Dominant in GLP-1 drugs (Ozempic/Wegovy); FY2024 revenue DKK 232B. Uses both E. coli and yeast fermentation.
Terumo Corporation
HQ JP10% share
Japanese medical-device maker; pen needles and injection systems.
HTL-Strefa S.A.
HQ PL8% share
Polish OEM maker of pen needles and safety lancets — large contract supplier.
Owen Mumford Ltd.
HQ GB8% share
UK medical-device maker; Unifine pen needles and injection devices.
Ypsomed(YPSN.SW)
HQ CH7% share
Swiss self-injection device maker; YpsoMate autoinjector platform. Carved out its diabetes unit to focus on GLP-1 self-injectors and signed a long-term autoinjector supply deal with Novo Nordisk.